ACPE accredits Western New England University College of Pharmacy
SPRINGFIELD, M.A. — The Accreditation Council for Pharmacy Education has fully accredited Western New England University College of Pharmacy.
“I am certain that the College of Pharmacy will be a nationally recognized leader in pharmacy education,” Western New England University President Anthony S. Caprio said. “The College of Pharmacy has developed an innovative curriculum under the remarkable leadership of Dean Evan Robinson, who has successfully recruited a highly talented faculty, to bring the College to this accreditation recognition.”
The college graduated its first class of Doctor of Pharmacy students in May.
“From the earliest stages of this endeavor everyone came together to develop the academic program literally from the ground up,” Evan Robinson, dean of the College of Pharmacy, said.
The first class of students consisted of about 75 students per year.
ACPE noted the strength of the college’s professional development sequence and the emphasis it places on professionalism.
The college is located within the 127,000-square-foot Center for the Sciences and Pharmacy, which opened in January 2011.
Sandoz launches generic Angiomax through Medicines Company partnership
PRINCETON, N.J. — Sandoz has launched its generic version of Angiomax (bivalirudin), an anticoagulant injection. The drug’s U.S. launch is the result of a supply and distribution agreement with the Medicines Company.
“This agreement with The Medicines Company for an authorized generic bivalirudin reflects our commitment to making high-quality generic injectables available to patients and healthcare professionals in the U.S.,” Sandoz President Peter Goldschmidt said.
Bivalirudin is an anticoagulant indicated for patients with unstable angina undergoing coronary angioplasty, as well as those undergoing percutaneous coronary intervention or those with heparin-induced thrombocytopenia, among other indications. IMS Health projected that in the 12 months ending in April 2015, the brand-name treatment sales were about $485 million.